Brain Targeting and Aβ Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice

• Published in: ACS chemical neuroscience Vol. 12; no. 12; pp. 2110 - 2121
• Main Authors: Zhang, Xiancheng, Zhang, Xiaoyu, Li, You, Zhong, Manli, Zhao, Pu, Guo, Chuang, Xu, He, Wang, Tao, Gao, Huiling
• Format: Journal Article
• Language: English
• Published: American Chemical Society 16.06.2021
• Subjects: β-amyloid peptide; Alzheimer’s disease; phage display peptide; bifunctional nanoparticles; brain targeting
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.1c00035

Alzheimer’s disease (AD) is an insidious and progressive neurodegenerative disease with few disease-modifying treatments. A variety of peptide/protein drugs have neuroprotective effects, which brings new hope for the treatment of AD. However, the application of these drugs is limited because of their low specificity and difficulty in crossing the blood–brain barrier. Herein, using the phage display technology, we identified the Aβ oligomer binding peptide (KH) and the brain targeting peptide (IS). We combined these peptides to develop a bifunctional nanoparticle (IS@NP/KH) for the delivery of Aβ1–42 oligomer binding peptide into the brain. Intranasal administration of IS@NP/KH significantly attenuated the cognitive and behavioral deficits and reduced the Aβ deposition in the brain of an AD animal model (APPswe/PS 1d9 double-transgenic mice). Our results suggest that intranasal IS@NP/KH administration could be a novel therapeutic strategy for the treatment of AD.